FOSUN PHARMA (02196.HK) +0.340 (+2.252%) Short selling $4.49M; Ratio 4.637% recently released internally its self-developed PharmAID decision agent platform, which is currently constructing a full lifecycle intelligent decision-making network covering innovative R&D scenarios, according to FOSUN PHARMA. The platform deeply integrates the world's leading foundation model technology, with AI translation, AI medical writing/ revision and other functions, and has taken the lead in accessing Deepseek R1 and a number of professional clinical information and pipeline data platforms around the world, enabling the accuracy rate of content generation in the medical and healthcare fields to be increased by 50% compared with that of general foundation models, with data updated on a “T+1” basis.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-03-28 16:25.)Related NewsFOSUN PHARMA's Full-Yr NP Soars 15.5% to RMB2.77B; Final Div. RMB32 Cents